What is Male Pattern Baldness?
Male pattern baldness — medically termed androgenetic alopecia — is the most common form of hair loss in men, affecting approximately 50% of men by age 50 and up to 70–80% by age 70. Despite its prevalence, it is frequently misunderstood, poorly managed, and needlessly accepted as inevitable.
The condition is characterised by a predictable pattern of hair loss that typically begins at the temples (receding hairline) and/or the vertex (crown), progressively expanding until large areas of the scalp are bald. The rate of progression varies enormously — some men progress rapidly through multiple Norwood stages in just a few years, while others remain at the same stage for decades.
The Role of DHT
The central mechanism of male pattern baldness is the action of dihydrotestosterone (DHT) on genetically susceptible hair follicles. DHT is produced from testosterone through the enzyme 5-alpha reductase (5αR). In genetically predisposed men, hair follicles on the top and front of the scalp have androgen receptors that are highly sensitive to DHT.
When DHT binds to these receptors, it initiates progressive miniaturisation: the anagen (growth) phase becomes progressively shorter with each cycle; the hair produced becomes progressively thinner, lighter, and shorter. Eventually, the follicle becomes dormant and no longer produces visible hair.
Critically, follicles on the back and sides (the donor zone) are genetically programmed to be DHT-resistant. This is why they remain even in advanced baldness — and why hair transplanted from this zone retains its DHT resistance in its new location, producing permanent results.
Transplanted follicles retain their genetic programming from the donor zone. They continue producing hair immune to DHT miniaturisation — growing naturally for life, just as they would have in their original location on the back and sides of the scalp.
The Norwood Scale: All 7 Stages
Mature adult hairline with no significant recession. No baldness. A mature hairline is normal in adult men and is not a sign of hair loss. No treatment required — monitor annually.
Slight temple recession creating a shallow M-shape. Crown typically unaffected. Often first appearance of androgenetic alopecia in mid-20s to early 30s.
Significant temple recession — deep M, U, or V-shaped hairline. Beginning of clinically significant baldness. Stage IIIvertex also has crown thinning.
Severe temple recession + clearly thinning or bald crown. Bridge of hair separates the two areas. Most common stage at which men seriously consider hair transplant.
Bridge between frontal and crown areas becomes very narrow. Both bald areas are large. Extensive coverage required for natural result. Donor planning important.
Bridge of hair gone. One large bald area covers most of the top of the scalp. Only horseshoe zone remains. Donor supply assessment critical.
Narrow horseshoe of hair at sides and back only. Limited scalp donor supply. Complex planning required. Body hair transplant may supplement.
Progression & Planning for the Future
Androgenetic alopecia is a progressive condition — it does not stabilise without treatment. The rate varies: rapid progressors move through 2–3 Norwood stages in their 20s–30s; moderate progressors show gradual change over 10–20 years; slow progressors may remain at Stage II–III for many years.
A transplant at Norwood Stage III without medical therapy risks continued recession behind the transplanted area — creating an unnatural result over time. Dr. Ashwini always develops a comprehensive long-term plan: typically surgical restoration combined with finasteride and/or minoxidil for prevention.
Treatment Options
Medical Treatments
- Finasteride (1mg daily): Inhibits 5-alpha reductase, reducing scalp DHT by ~70%. Halts progression in ~85% of men; visible regrowth in ~65%. Requires lifelong use.
- Minoxidil (topical 5% or oral 0.5–1.25mg): Extends anagen phase and increases follicle size. Oral minoxidil has shown superior efficacy to topical in recent studies.
- Dutasteride: More potent than finasteride — inhibits both type 1 and type 2 5-alpha reductase, reducing DHT by up to 90%.
Regenerative Treatments
- PRP Therapy: Most effective in early-stage androgenetic alopecia — stimulates follicles and reduces shedding.
- GFC Therapy: Higher growth factor concentration than PRP — often preferred for men who have not responded adequately to PRP alone.
Surgical Treatments (Permanent)
- Sapphire FUE: Gold standard — precision sapphire blade channel creation. Minimal scarring, rapid healing, maximum density.
- DHI: CHOI pen implantation — precise angle and direction control. Ideal for density in partially hair-bearing areas.
- Bio FUE & Stem Cell FUE: Enhanced FUE with biological agents for superior graft survival and regrowth.